Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says

 
• By Brenda Sandburg
  
Creative pathway
Creative approach is needed for approval of rare disease treatments • Source: Shutterstock

More from Rare Diseases

More from Conferences